Business Wire

Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple ...
Nasdaq

Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology ...